학술논문

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
Document Type
Report
Source
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. September, 2019, p1897, 15 p.
Subject
Mortality
Low density lipoproteins -- Health aspects
Atherosclerosis -- Care and treatment -- Risk factors -- Health aspects
Anticholesteremic agents -- Health aspects
Type 2 diabetes -- Care and treatment -- Risk factors -- Health aspects
Diabetes therapy -- Health aspects
Cholesterol -- Health aspects
Cardiac patients -- Care and treatment -- Health aspects
Cardiovascular diseases -- Care and treatment -- Risk factors -- Health aspects
Diabetics -- Care and treatment -- Health aspects
Alirocumab
Evolocumab
Anopheles
Peripheral vascular diseases
Lipids
Morbidity
Ezetimibe
Antilipemic agents
Statins
Retirement benefits
Language
English
ISSN
1178-7007
Abstract
Diabetes is a significant and independent risk factor for atherosclerotic cardiovascular disease (ASCVD), leading to morbidity and mortality among this population. The prevention of macrovascular complications, such as CVD, peripheral arterial disease, and cerebrovascular accident, in patients with diabetes is obtained through multifactorial risk reduction, including mixed dyslipidemia management and adequate glycemic control. For patients with diabetes, it is crucial to initiate adequate dyslipidemia therapy to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal of
Introduction Over the last few decades, there has been a drastic increase in the prevalence of type 2 diabetes (T2D) within the United States, with numbers reaching over 30 million [...]